Marker-free plasmids for biotechnological applications - implications and perspectives

Trends in Biotechnology

Volumn 31, Issue 9, 2013, Pages 539-547

  Oliveira, Pedro H ^a,b   Mairhofer, Juergen ^c  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

Author keywords

Antibiotic resistance; DNA vaccines; Gene therapy; Genetically modified plants; Plasmid vector design; Stem cells.

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC RESISTANCE GENES; BIOTECHNOLOGICAL APPLICATIONS; DNA VACCINE; GENETIC INFORMATION; NONVIRAL GENE THERAPY; PLASMID INSTABILITY; PLASMID VECTORS;

ANTIBIOTICS; BIOTECHNOLOGY; GENE THERAPY; GENE TRANSFER; GENETICALLY MODIFIED PLANTS; STEM CELLS; VACCINES;

DNA;

ANTIBIOTIC AGENT; DNA VACCINE; KANAMYCIN; NEOMYCIN; PLASMID DNA; RECOMBINANT PROTEIN;

ANTIBIOTIC RESISTANCE; BIOSAFETY; BIOTECHNOLOGICAL PROCEDURES; CLINICAL TRIAL (TOPIC); CROP; DNA VECTOR; DRUG SAFETY; GENE SILENCING; HUMAN; IMMUNOGENICITY; MOLECULAR INTERACTION; MOLECULAR STABILITY; NONHUMAN; NONSENSE MUTATION; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STEM CELL; TRANSGENIC PLANT;

EID: 84882708788     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.06.001     Document Type: Review

References (83)

1. Azzoni A.R., et al. The impact of polyadenylation signals on plasmid nuclease-resistance and transgene expression. J. Gene Med. 2007, 9:392-402.
2. Coban C., et al. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J. Leukoc. Biol. 2005, 78:647-655.
3. Uchijima M., et al. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J. Immunol. 1998, 161:5594-5599.
4. Mairhofer J., et al. A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy. Biotechnol. J. 2008, 3:83-89.
5. FDA Points to consider on plasmid DNA vaccines for preventive infectious disease indications. Cent. Biol. Eval. Res. 1996, Docket No. 96N-0400.
6. Darquet A.M., et al. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 1997, 4:1341-1349.
7. Bigger B.W., et al. An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J. Biol. Chem. 2001, 276:23018-23027.
8. Chen Z.Y., et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. 2003, 8:495-500.
9. Jechlinger W., et al. Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J. Mol. Microbiol. Biotechnol. 2004, 8:222-231.
10. Schleef M. Minicircle and Miniplasmid DNA Vectors: The Future of Non-Viral and Viral Gene Transfer 2013, Wiley-VCH.
11. Soubrier F., et al. pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Ther. 1999, 6:1482-1488.
12. Soubrier F., et al. Improvement of pCOR plasmid copy number for pharmaceutical applications. Appl. Microbiol. Biotechnol. 2005, 66:683-688.
13. Fabre E.E., et al. Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment. Genet. Vaccines Ther. 2008, 6:10.
14. Nikol S., et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 2008, 16:972-978.
15. Maulik N. NV1FGF, a pCOR plasmid-based angiogenic gene therapy for the treatment of intermittent claudication and critical limb ischemia. Curr. Opin. Investig. Drugs 2009, 10:259-268.
16. Marie C., et al. pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. J. Gene Med. 2010, 12:323-332.
17. Williams S.G., et al. Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res. 1998, 26:2120-2124.
18. Cranenburgh R.M., et al. Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res. 2001, 29:E26.
19. Guimaraes-Walker A., et al. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008, 26:6671-6677.
20. Jaoko W., et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26:2788-2795.
21. McCormack S., et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26:3162-3174.
22. Garmory H.S., et al. Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium. Infect. Immun. 2005, 73:2005-2011.
23. Leckenby M.W., et al. Enhanced vaccine antigen delivery by Salmonella using antibiotic-free operator-repressor titration-based plasmid stabilisation compared to chromosomal integration. Microb. Pathog. 2009, 46:201-206.
24. Huang J.M., et al. Oral delivery of a DNA vaccine against tuberculosis using operator-repressor titration in a Salmonella enterica vector. Vaccine 2010, 28:7523-7528.
25. Luke J., et al. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 2009, 27:6454-6459.
26. Mairhofer J., et al. Marker-free plasmids for gene therapeutic applications-lack of antibiotic resistance gene substantially improves the manufacturing process. J. Biotechnol. 2010, 146:130-137.
27. Ribeiro S., et al. Plasmid DNA size does affect nonviral gene delivery efficiency in stem cells. Cell. Reprogram. 2012, 14:130-137.
28. Lu J., et al. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. Mol. Ther. 2013, 21:954-963.
29. Furger A., et al. Promoter proximal splice sites enhance transcription. Genes Dev. 2002, 16:2792-2799.
30. Wellington E.M., et al. The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. Lancet Infect. Dis. 2013, 13:155-165.
31. Chen J., et al. A survey of drug resistance bla genes originating from synthetic plasmid vectors in six Chinese rivers. Environ. Sci. Technol. 2012, 46:13448-13454.
32. Rozkov A., et al. Characterization of the metabolic burden on Escherichia coli DH1 cells imposed by the presence of a plasmid containing a gene therapy sequence. Biotechnol. Bioeng. 2004, 88:909-915.
33. Mahillon J., Chandler M. Insertion sequences. Microbiol. Mol. Biol. Rev. 1998, 62:725-774.
34. Prather K.L., et al. Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines. Appl. Microbiol. Biotechnol. 2006, 73:815-826.
35. Oliveira P.H., et al. Deletion formation mutations in plasmid expression vectors are unfavored by runaway amplification conditions and differentially selected under kanamycin stress. J. Biotechnol. 2009, 143:231-238.
36. Szeverenyi I., et al. Vector for IS element entrapment and functional characterization based on turning on expression of distal promoterless genes. Gene 1996, 174:103-110.
37. Oliveira P.H., et al. Analysis of DNA repeats in bacterial plasmids reveals the potential for recurrent instability events. Appl. Microbiol. Biotechnol. 2010, 87:2157-2167.
38. Ribeiro S.C., et al. High frequency plasmid recombination mediated by 28bp direct repeats. Mol. Biotechnol. 2008, 40:252-260.
39. Bi X., Liu L.F. A replicational model for DNA recombination between direct repeats. J. Mol. Biol. 1996, 256:849-858.
40. Oliveira P.H., et al. Recombination frequency in plasmid DNA containing direct repeats-predictive correlation with repeat and intervening sequence length. Plasmid 2008, 60:159-165.
41. Borgi I., Gargouri A. A spontaneous direct repeat deletion in the pGEX fusion vector decreases the expression level of recombinant proteins in Escherichia coli. Protein. Expr. Purif. 2008, 60:15-19.
42. Kim M., et al. A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies. Biotechnol. Bioeng. 2011, 108:2434-2446.
43. Valera A., et al. Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism. Hum. Gene Ther. 1994, 5:449-456.
44. Nejepinska J., et al. Deep sequencing reveals complex spurious transcription from transiently transfected plasmids. PLoS ONE 2012, 7:e43283.
45. Dutta P., et al. Global epigenetic changes induced by SWI2/SNF2 inhibitors characterize neomycin-resistant mammalian cells. PLoS ONE 2012, 7:e49822.
46. Yamamoto S., et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J. Immunol. 1992, 148:4072-4076.
47. Krieg A.M., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
48. Yew N., et al. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol. Ther. 2000, 1:255-262.
49. Yew N., et al. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol. Ther. 2002, 5:731-738.
50. Hyde S.C., et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat. Biotechnol. 2008, 26:549-551.
51. Navarro G., et al. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery. J. Control. Release 2010, 146:99-105.
52. Higgins D., et al. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev. Vaccines 2007, 6:747-759.
53. Kosovac D., et al. Minimal doses of a sequence-optimized transgene mediate high-level and long-term EPO expression in vivo: challenging CpG-free gene design. Gene Ther. 2010, 18:189-198.
54. Bauer A.P., et al. The impact of intragenic CpG content on gene expression. Nucleic Acids Res. 2010, 38:3891-3908.
55. Lesina E., et al. CpG-free plasmid DNA prevents deterioration of pulmonary function in mice. Eur. J. Pharm. Biopharm. 2010, 74:427-434.
56. Lesina E., et al. The effect of CpG motifs on gene expression and clearance kinetics of aerosol administered polyethylenimine (PEI)-plasmid DNA complexes in the lung. J. Control. Release 2010, 143:243-250.
57. Davies L.A., et al. The use of CpG-free plasmids to mediate persistent gene expression following repeated aerosol delivery of pDNA/PEI complexes. Biomaterials 2012, 33:5618-5627.
58. Suzuki M., et al. Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J. Virol. 2006, 80:3293-3300.
59. Riu E., et al. Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol. Ther. 2007, 15:1348-1355.
60. Riu E., et al. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum. Gene Ther. 2005, 16:558-570.
61. Chen Z., et al. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther. 2004, 11:856-864.
62. Gracey Maniar L.E., et al. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol. Ther. 2013, 21:131-138.
63. Lu J., et al. The extragenic spacer length between the 5' and 3' ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors. Mol. Ther. 2012, 20:2111-2119.
64. Marineau B. First Fruit: the Creation of the Flavr Savr Tomato and the Birth of Genetically Engineered Food 2001, McGraw-Hill.
65. Darbani B., et al. Methods to produce marker-free transgenic plants. Biotechnol. J. 2007, 2:83-90.
66. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
67. Si-Tayeb K., et al. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev. Biol. 2010, 10:81.
68. Jia F., et al. A nonviral minicircle vector for deriving human iPS cells. Nat. Methods 2010, 7:197-199.
69. Narsinh K.H., et al. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat. Protoc. 2011, 6:78-88.
70. Madeira C., et al. Nonviral gene delivery to neural stem cells with minicircles by microporation. Biomacromolecules 2013, 13:1379-1387.
71. Chabot S., et al. Minicircle DNA electrotransfer for efficient tissue-targeted gene delivery. Gene Ther. 2012, 20:62-68.
72. Peubez I., et al. Antibiotic-free selection in E. coli: new considerations for optimal design and improved production. Microb. Cell Fact. 2010, 9:65.
73. Vidal L., et al. Development of an antibiotic-free plasmid selection system based on glycine auxotrophy for recombinant protein overproduction in Escherichia coli. J. Biotechnol. 2008, 134:127-136.
74. Dong W.R., et al. Novel antibiotic-free plasmid selection system based on complementation of host auxotrophy in the NAD de novo synthesis pathway. Appl. Environ. Microbiol. 2010, 76:2295-2303.
75. Kaufman W.L., et al. Homogeneity and persistence of transgene expression by omitting antibiotic selection in cell line isolation. Nucleic Acids Res. 2008, 36:e111.
76. Lanza A.M., et al. Evaluating the influence of selection markers on obtaining selected pools and stable cell lines in human cells. Biotechnol. J. 2013, 8:811-821.
77. Kacherovsky N., et al. Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells. Nucleic Acids Res. 2012, 40:e85.
78. Wright O., et al. Building-in biosafety for synthetic biology. Microbiology 2013, 159:1221-1235.
79. Lewis L.A., et al. Protein-DNA interactions define the mechanistic aspects of circle formation and insertion reactions in IS2 transposition. Mobile DNA 2012, 3:1.
80. Ribeiro S.C., et al. The role of polyadenylation signal secondary structures on the resistance of plasmid vectors to nucleases. J. Gene Med. 2004, 6:565-573.
81. Lukacs G.L., et al. Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. 2000, 275:1625-1629.
82. Kreiss P., et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res. 1999, 27:3792-3798.
83. Yin W., et al. Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal. Biochem. 2005, 346:289-294.